Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB) -- Ignore unavailable to you. Want to Upgrade?

To: Bill Wexler who wrote (407)	12/23/1997 1:11:00 PM
From: npguy	Read Replies (2) \| Respond to of 834

but before you do, perhaps you may want to talk to some biochem people at a local university. Since you are implying the rest of us have no clue as to the validity of TXB science, why don't you enlighten us with your version of what's wrong with TXB's science. So far, when pressed, you keep saying this company is a scam. Well, why is it a scam? You have not offered anything of substance. If you have something to contribute then do it. If all you are interested in saying is "this company is a scam", then by all means do it to your heart content. My time is too valuable to spend in debating a claim out of thin air.

To: Bill Wexler who wrote (407)	12/26/1997 3:43:00 PM
From: X. Fang	Read Replies (1) \| Respond to of 834

Dear Mr. Wexler, I've been investing in TXb for several years. Your claim that TXB is a total scam sounds very scary to me. Before I consider to sell my holdings, I would like to ask you a few questions. (I assume that you must be a expert in Biotech-investment and have done the research on TBC throughly). 1. Why don't you think TXB is an expert in the field of "computer-aided small molecule drug design"? When you visited the company, what kind of equipment were they using? What kind of equipment do you expect an expert in their field should use? Can you give me an example of a good company in the field of "computer-aided small molecule drug design"? And pardon me if sounds stupid, what is "computer-aided small molecule drug design"? 2. Two analysts from Lehman Brother, Dr. Butler and Mr. Rouse, started to cover TXB with a "Strong Buy" rating about 8 month ago. As I understand, they are reputable analysts and have very good track records. They even played the major roles in the secondary offering of TXB. Why do you think they are willing to risk their reputation and creer in a scam company TBC, especially such a small company? 3. About the FDA review. You said 'A lot is made of the "priority review" process.' What percentage of NDA filings is granted "priority review" by FDA? A friend of mine told me is 9%, this is quite different from "a lot". 4. Why do you think "Novastan will be rejected"? The drug has been using in Japan for over 3 years without any negative report. Could you please give me some explanation on your conclusion? it's a huge thing. Thank you very much for your time. Sean